Cardiopulmonary bypass (CPB) priming dilutes more than hematocrit. It also changes circulating albumin concentration, with potential implications for colloid osmotic pressure and fluid distribution. Julie Fenske and Isabel Centner describe a spreadsheet-based model intended to make that dilution visible and estimate albumin requirements for a selected concentration target. The publication introduces a calculation tool; it does not demonstrate improved patient outcomes.
Why consider albumin dilution during bypass?
A fixed albumin dose in the prime can have different dilutional effects depending on the patient’s circulating volume, baseline albumin concentration, and the volume and composition of the circuit prime. The authors propose extending the familiar concept of dilutional hematocrit to albumin management.
The physiologic rationale centers on albumin’s contribution to plasma colloid osmotic pressure. However, fluid movement during and after CPB also reflects endothelial permeability, inflammation, hydrostatic pressure, lymphatic drainage, and overall fluid balance. Preserving a calculated albumin concentration should not be equated with preventing capillary leak or postoperative edema.
What the investigators developed
The authors reviewed relevant literature and assembled equations for albumin content, dilution at CPB initiation, and albumin supplementation for a user-selected circulating concentration. They implemented these calculations in Google Sheets, with an interface that can also be recreated in compatible spreadsheet software.
This is a model-development report. No patients or animals were enrolled, and the paper reports no prospective validation, randomized comparison, or measured clinical outcomes from using the calculator.
Inputs and practical safeguards
The model incorporates patient and circuit variables to estimate the dilutional effect of the prime. Its interface includes protected calculation cells, acceptable input ranges, and a reset function intended to reduce accidental overwriting, unit errors, and carryover of data from a previous case. The authors describe clearing inputs on opening and after 15 minutes of inactivity.
These design features address common spreadsheet-use errors, but they do not establish clinical validity. Accurate units, current laboratory values, appropriate volume estimates, and an independently checked implementation remain essential when evaluating such a tool.
What the model can—and cannot—show
The calculator estimates how a given prime and albumin addition change the predicted circulating concentration. It can illustrate why a standard fixed dose may not preserve the starting concentration in every patient. The authors particularly highlight patients whose circulating volume is small relative to the prime, including underweight, hypovolemic, and pediatric patients.
Those populations are proposed areas of relevance, not subgroups with demonstrated benefit in this study. The paper does not establish an optimal albumin target, a recommended dosing protocol, or a reduction in renal injury, pulmonary complications, length of stay, or mortality.
Interpreting the oncotic-pressure rationale
The discussion relates albumin dilution to published relationships between plasma protein concentration and colloid osmotic pressure. These relationships provide a physiologic framework, but a calculated pressure change is not a direct measurement of the patient’s microvascular fluid exchange.
The distinction matters during CPB, when changes in vascular permeability and other forces may alter the relationship between circulating protein concentration and tissue edema. A concentration model therefore describes one component of a larger fluid-management problem.
Limitations and next steps
The main limitation is the absence of clinical validation. The report does not compare predicted with measured albumin concentrations across a patient cohort, quantify model error, or test whether model-guided administration improves outcomes compared with standard practice.
Likewise, maintaining a pre-bypass albumin concentration has not been shown here to be the best treatment target. Illustrative calculations are not evidence that the associated albumin quantities should be adopted routinely. The authors identify a prospective clinical comparison as a future research direction.
Further evaluation would need to address both prediction accuracy and clinically meaningful outcomes, alongside the consequences of additional albumin and fluid administration. Pediatric application would require specific assessment rather than extrapolation from adult examples.
Relevance for perfusion practice
The educational value is straightforward: prime composition can be evaluated in relation to the individual patient rather than discussed only as a standard recipe. The model offers a structured way to examine albumin dilution and generate research questions. It should be understood as an investigational calculation framework, with patient benefit still to be established.
Source: Fenske J, Centner I. A predictive model for prudent albumin priming in cardiopulmonary bypass circuits. Journal of ExtraCorporeal Technology. 2026;58:223–227. doi:10.1051/ject/2026016.
Funding and disclosures: The authors report no funding and no conflicts of interest. The source article is distributed under CC BY 4.0. This IPA educational summary is independently paraphrased; the downloadable source PDF is unchanged.
